Newsroom press releases

17/12/24 - 12:56

2025 Annual Calendar of Corporate Events (104.79 KB)

Download

11/11/24 - 7:38

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)

Products Molecular

Download

05/11/24 - 16:27

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)

Financial Data

Download

27/09/24 - 7:35

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)

Products Molecular

Download

09/09/24 - 13:11

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)

Products Immunodiagnostic

Download

05/09/24 - 11:17

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)

Other

Download

04/09/24 - 11:36

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)

Other

Download

29/07/24 - 15:55

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)

Financial Data

Download

16/07/24 - 8:31

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)

Products Molecular

Download

05/06/24 - 5:07

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)

Products Molecular

Download

16/05/24 - 19:56

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)

Products Molecular

Download

10/05/24 - 15:21

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)

Financial Data

Download

24/04/24 - 15:38

Shareholders' Meeting 2024 (159.72 KB)

Other

Download

16/04/24 - 8:20

Communication on total amount of voting rights (135.47 KB)

Other

Download

15/03/24 - 13:35

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)

Financial Data

Download

13/03/24 - 10:23

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)

Products Molecular

Download

03/03/24 - 19:32

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)

Products Molecular

Download

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)

Products Immunodiagnostic

Download

11/11/15 - 1:00

The Board of Directors approves the results for Q3'15 (778.06 KB)

Financial Data

Download

09/09/15 - 2:00

DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias (229.24 KB)

Products Molecular

Download

30/07/15 - 2:00

H1'15 Results (777.06 KB)

Financial Data

Download

20/07/15 - 2:00

DiaSorin and Beckman Coulter sign a distribution agreement for China (238.01 KB)

Acquisition / Partnership

Download

28/05/15 - 2:00

DiaSorin launches the test for Campylobacter (241.86 KB)

Products Immunodiagnostic

Download

12/05/15 - 2:00

The Board of Directors approves the results for Q1'15 (553.96 KB)

Financial Data

Download

12/05/15 - 2:00

DiaSorin presents the 2015-2017 industrial plan (305.81 KB)

Other

Download

29/04/15 - 2:00

DiaSorin - launches the test for Brahms-Sepsis (506.96 KB)

Products Immunodiagnostic

Download

23/04/15 - 2:00

DiaSorin supports the Pinocchio Project (251.16 KB)

Download

22/04/15 - 2:00

The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day (141.85 KB)

Financial Data

Download

22/04/15 - 2:00

Shareholders' meeting approves FY Results 2014 (105.93 KB)

Financial Data

Download

14/04/15 - 2:00

DiaSorin launches the tests for Bordetella pertussis (187.11 KB)

Products Immunodiagnostic

Download

10/04/15 - 2:00

Investor Day-save the date (107.93 KB)

Financial Data

Download

24/03/15 - 1:00

DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation (504.27 KB)

Download

03/03/15 - 1:00

The Board of Directors approves the results for FY'14 (783.03 KB)

Financial Data

Download

24/02/15 - 1:00

DiaSorin supports Emergency in Sudan (612.64 KB)

Download

13/02/15 - 1:00

DiaSorin teams with FISIP for Progetto talenti (612.64 KB)

Download

14/01/15 - 1:00

DiaSorin launches the test for Calprotectin (259.67 KB)

Products Immunodiagnostic

Download

Newsroom press releases

Select year

Newsroom press category

2025 Annual Calendar of Corporate Events (104.79 KB)

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)

DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)

Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)

Shareholders' Meeting 2024 (159.72 KB)

Communication on total amount of voting rights (135.47 KB)

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)

The Board of Directors approves the results for Q3'15 (778.06 KB)

DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias (229.24 KB)

H1'15 Results (777.06 KB)

DiaSorin and Beckman Coulter sign a distribution agreement for China (238.01 KB)

DiaSorin launches the test for Campylobacter (241.86 KB)

The Board of Directors approves the results for Q1'15 (553.96 KB)

DiaSorin presents the 2015-2017 industrial plan (305.81 KB)

DiaSorin - launches the test for Brahms-Sepsis (506.96 KB)

DiaSorin supports the Pinocchio Project (251.16 KB)

The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day (141.85 KB)

Shareholders' meeting approves FY Results 2014 (105.93 KB)

DiaSorin launches the tests for Bordetella pertussis (187.11 KB)

Investor Day-save the date (107.93 KB)

DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation (504.27 KB)

The Board of Directors approves the results for FY'14 (783.03 KB)

DiaSorin supports Emergency in Sudan (612.64 KB)

DiaSorin teams with FISIP for Progetto talenti (612.64 KB)

DiaSorin launches the test for Calprotectin (259.67 KB)

Price Sensitive